Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Bon-Kwan Goo"'
Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome
Publikováno v:
The Korean Journal of Internal Medicine, Vol 34, Iss 2, Pp 390-400 (2019)
Background/Aims Various alterations of microRNA (miRNA) expression have been reported in myelodysplastic syndrome (MDS). We aimed to investigate the unique patterns and prognostic significance of miRNA expression in Korean patients with MDS. Methods
Externí odkaz:
https://doaj.org/article/09f66a9bce814084b1bc6209ebd44516
Autor:
Miee Seol, Juhyun Moon, Eun-Hye Hur, Young-Shin Lee, Kyoo-Hyung Lee, Eun-Ji Choi, Jung-Hee Lee, Han-Seung Park, Je-Hwan Lee, Yeon Hee Kim, Young-Ah Kang, Mijin Jeon, Ji Min Woo, Bon-Kwan Goo, Sun-Hye Ko
Publikováno v:
Leukemia Research. 68:51-56
This retrospective analysis compared anthracyclines (as part of an induction regimen) in 128 newly diagnosed FLT3-ITD-mutated AML patients. Induction regimens comprised high-dose daunorubicin (HD-DN; 90 mg/m2/d × 3d; n = 44), standard-dose daunorubi
Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells
Autor:
Juhyun Moon, Gilnam Lee, Suk Young Cho, Yunsuk Choi, Jene Choi, Choung-Soo Kim, Sang-Hwa Yang, Kyun-Seop Bae, Jeongbeob Seo, Je-Hwan Lee, Bon-Kwan Goo, Jung Jin Hwang, Eun-Hye Hur
Publikováno v:
Oncotarget
Primary or acquired resistance to MEK inhibitors has been a barrier to successful treatment with MEK inhibitors in many tumors. In this study, we analyzed genome-wide gene expression profiling data from 6 sensitive and 6 resistant cell lines to ident
Autor:
Je-Hwan Lee, Bon-Kwan Goo, Yunsuk Choi, Dae Ro Choi, Seung-Hyun Jung, Yeun-Jun Chung, Eun-Hye Hur, Juhyun Moon
Publikováno v:
Oncotarget
// Eun-Hye Hur 1, * , Seung-Hyun Jung 2, 3, * , Bon-Kwan Goo 1 , Juhyun Moon 1 , Yunsuk Choi 4 , Dae Ro Choi 5 , Yeun-Jun Chung 3, 6 , Je-Hwan Lee 1 1 Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Kore
Autor:
Bon-Kwan Goo, Yong-Rim Kwon, Seung-Hyun Jung, Yunsuk Choi, Je-Hwan Lee, Eun-Hye Hur, Sug Hyung Lee, Yeun-Jun Chung, Yoo-Jin Kim, Hye-Jung Kim, Seon-Hee Yim
Publikováno v:
Oncotarget
Although hypomethylating therapy (HMT) is the first line therapy in higher-risk myelodysplastic syndromes (MDS), predicting response to HMT remains an unresolved issue. We aimed to identify mutations associated with response to HMT and survival in MD
Autor:
Yunsuk Choi, Yonggoo Kim, Seung-Hyun Jung, Eun Young Choi, Eun-Hye Hur, Juhyun Moon, Jung-Shin Lee, Bon-Kwan Goo, Yeun-Jun Chung
Publikováno v:
Leukemia Research. 39:S82
Publikováno v:
Cancer Research. 74:1499-1499
Introduction: MicroRNAs (miRNAs) are short non-coding RNAs that are involved in post-transcriptional regulation of gene expression, which may result in translational inhibition or destabilization of the target mRNA. Various alterations of miRNA expre
Autor:
Suk Young Cho, Yunsuk Choi, Choung-Soo Kim, Sang-Hwa Yang, Jung Jin Hwang, Bon-Kwan Goo, Eun-Hye Hur, Jene Choi, Je-Hwan Lee, Kyun-Seop Bae, Sung-Doo Kim
Publikováno v:
Cancer Research. 74:5455-5455
The important role of Ras/Raf/MEK/ERK pathway in carcinogenesis has led to clinical development of MEK inhibitors for treatment of various cancers. Although recent studies have demonstrated impressive antitumor activities of the agents, many tumors s
Autor:
Ju Hyun Moon, Je-Hwan Lee, Do Young Lee, Seonggu Ro, Eun-Hye Hur, Yunsuk Choi, Joong Myung Cho, Bon-Kwan Goo, Dae R. Choi
Publikováno v:
Cancer Research. 74:399-399
Myelodysplastic syndrome (MDS) is a clonal disorder of the hematopoietic cells occurring in elderly patients in a majority of instances. They are defined by ineffective hematopoiesis with peripheral blood cytopenias and by the risk of evolution to ac
Autor:
Je-Hwan Lee, Kyoo-Hyung Lee, Minhee Kim, Yunsuk Choi, Seonggu Ro, Choung-Soo Kim, Junghee Lee, Eun-Hye Hur, Dae-Young Kim, Sung-Doo Kim, Jung Jin Hwang, Bon-Kwan Goo
Publikováno v:
Cancer Research. 72:4666-4666
Background: Acute myeloid leukemia (AML) can be cured by cytotoxic chemotherapy, but about half of patients with AML fail to obtain long-term survival, mostly due to chemotherapy-resistance. Novel therapeutic approaches are needed to overcome the res